Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. The Dow Jones Industrial Average ( ^DJI) is trading up 53 points (+0.4%) at 13,038 as of Thursday, Nov 29, 2012, 1:35 p.m. ET. During this time, 368.2 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 628.6 million. The NYSE advances/declines ratio sits at 2,100 issues advancing vs. 843 declining with 121 unchanged.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The Dow component leading the way higher looks to be Pfizer (NYSE: PFE), which is sporting a 24-cent gain (+0.9%) bringing the stock to $24.90. This single gain is lifting the Dow Jones Industrial Average by 1.82 points or roughly accounting for 3.4% of the Dow's overall gain. Volume for Pfizer currently sits at 20.1 million shares traded vs. an average daily trading volume of 28.9 million shares. Pfizer has a market cap of $178.54 billion and is part of the health care sector and drugs industry. Shares are up 12.1% year to date as of Wednesday's close. The stock's dividend yield sits at 3.6%. Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. The company has a P/E ratio of 18.8, above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.